Featured Education

p24036-wcirdc-lms-thumb_1735917426
nmdp-mds3_1729518959
soho-2024-enduring-banner-445x250-02-02-02_1727985795
p24011-lms-thumb_1726675197
P23033 LMS Thumb
p24034-obesity-aafp-lms-thumbnail-445x250px_1723738749

On Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice / Activity 2
  • Credit: 0.50hr(s)
  • AAPA, CME, CPE, NCPD
  • February 17, 2023 — 
  • September 30, 2024
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: NSCLC, Oncology
  • Location: Internet Activity Enduring
This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points to metastatic NSCLC (mNSCLC) patient cases while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in mNSCLC and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 1 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies for an in-depth dive into the data!
Access Course
  • On-Demand
Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis
  • Credit: 1.00hr(s)
  • ILNA, NCPD
  • July 15, 2024 — 
  • July 14, 2025
  • Specialties: Hematology, Myelofibrosis, Oncology
  • Location: Internet Activity Enduring
In on-demand activity, Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, learn from expert faculty, Jeanne Palmer, MD and Jennifer Andres, APRN, FNP, MSN as they discuss Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, to effectively identify how JAK inhibitors and emerging treatments for myelofibrosis (MF) can optimize clinical outcomes and patient quality of life (QOL). Gain expert insights from enduring online program focuses on patient risk and drug mechanisms of action for effective treatment and management, gaps in MF care that influence patient QOL, disease- and treatment-related adverse events, trust with patients to improve outcomes and QOL, as well as shared decision-making and the unique role of multidisciplinary teams.
Access Course
  • On-Demand
The Importance of Being Honest
  • Credit: 0.25hr(s)
  • CME
  • September 16, 2024 — 
  • September 15, 2025
  • Therapeutic Areas: Oncology
  • Specialties: Breast Cancer
  • Location: Internet Activity Enduring
Of everything we do for our patients, the most important thing we can give them is honesty. What you will learn from this module: Learn that being honest with patients about their disease and its prognosis is very important for patients to know so they can plan out the remainder of their lives. Honesty doesn’t take away hope; it helps the patient move through phases of hope. 50% of the time, doctors do not disclose the patients’ actual prognosis. Patients do not understand or know the difference between palliative chemotherapy and active chemotherapy treatments, unless they are told.  Teaching patients to be optimistic for as long as it is realistic, while having an end of life plan in place should be our mantra. Avoidance of honesty may be linked to an oncologist’s feelings of believing they have failed the patient by not being able to save or sustain their life.
Access Course
  • On-Demand
Setting Up Patients for HCT and Cell Therapy Success
  • Credit: 1.00hr(s)
  • CME, NCPD
  • February 22, 2024 — 
  • February 20, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
  • Specialties: Bone Marrow Transplantation, Hematology, Oncology
  • Location: Internet Activity Enduring
This self-guided course provides practical recommendations and guidance on what hematology/oncology practices can do to improve patient experience and outcomes before their patient reaches a transplant center for consultation for Hematopoietic Cell Transplantation (HCT).
Access Course
  • On-Demand
Shared Decision Making
  • Credit: 0.50hr(s)
  • CME
  • September 16, 2024 — 
  • September 15, 2025
  • Therapeutic Areas: Oncology
  • Specialties: Breast Cancer
  • Location: Internet Activity Enduring
It is a process that fosters shared decision making that includes exploring and comparing the benefits, harms, and risks of each health care option through meaningful dialogue about what matters most to the patient. The doctor and patient need to use evidence-based information while working together to make the best possible treatment decisions.
Access Course
  • On-Demand
The Evolution of HCT, Part 3: Donor Availability
  • Credit: 0.75hr(s)
  • CME, NCPD
  • February 22, 2024 — 
  • February 20, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
  • Specialties: Bone Marrow Transplantation, Hematology, Oncology
  • Location: Internet Activity Enduring
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 3 in a 5-part series, covering advances in donor availability that have led to expanded access to HCT over time.
Access Course
View All MLI Activities
Facebook Twitter Linkedin Instagram
Subscribe to Mailing List
Scroll to Top